Testing AK104 and Lenvatinib with TACE for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests if adding a new combination of drugs (AK104 and lenvatinib) to a standard liver cancer procedure called TACE is more effective than TACE alone. It is for people whose liver cancer has not spread and cannot be removed by surgery, but who are well enough to receive these treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of liver cancer called hepatocellular carcinoma (HCC).
- Your liver cancer must not have spread to other parts of your body.
- You cannot have surgery to remove the cancer or a liver transplant, but you can receive TACE, a procedure that blocks the tumor's blood supply.
- Your liver function must be good (Child-Pugh score A), and you should be fairly active (ECOG score 0 or 1).
- You must not have had certain health problems like uncontrolled high blood pressure, bleeding in the past 6 months, or recent blood clots.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination of drugs (an immunotherapy called AK104 plus a targeted therapy called lenvatinib) compared to lenvatinib alone, for people whose liver cancer has grown after they received the standard first-line treatment with atezolizumab and bevacizumab. The goal is to see if combining the two drugs can better control the cancer and help patients live longer.
This trial tests a combination of a procedure that delivers chemotherapy directly to the liver tumor (called TACE) with an oral targeted therapy drug (lenvatinib) for people with liver cancer that cannot be removed with surgery. The goal is to see if this combination can shrink tumors more effectively than TACE alone.
This trial tests a combination of targeted therapy (lenvatinib), immunotherapy (PD-1 inhibitor), and a procedure called TACE (which delivers chemotherapy directly to the liver tumor) for people whose liver cancer has ruptured. The goal is to stop bleeding and shrink the tumor.
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
This trial tests a combination of two immunotherapy drugs for people with advanced liver cancer that has progressed after first-line treatment. It aims to see if this combination can help control the cancer.
This trial tests whether AK104, taken after liver cancer surgery, can lower the chance that the cancer returns. It is for people with high risk of recurrence but no remaining cancer after surgery.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.